A Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of Shingles vaccine candidate adjuvanted with CpG 1018 compared to the leading marketed shingles vaccine in the USA
Latest Information Update: 16 Nov 2022
At a glance
- Drugs Z 1018 (Primary)
- Indications Varicella zoster virus infections
- Focus Adverse reactions
- Sponsors Dynavax Technologies
- 18 Jan 2022 New trial record
- 10 Jan 2022 According to a Dynavax Technologies media release, topline data from this phase 1 clinical trial is expected by the end of 2022.